Treatment of Cutaneous Leishmaniasis with Cryosurgery

Overview

Journal Int J Dermatol

Specialty Dermatology

Date 2005 Sep 2

PMID 16135144

Citations 11

Authors

Antonios Panagiotopoulos

Panagiotis G Stavropoulos

Vassiliki Hasapi

Anastasia-Metaxia Papakonstantinou

Athanassios Petridis

Andreas Katsambas

Affiliations

Soon will be listed here.

Abstract

Background: The management of cutaneous leishmaniasis with topical methods, if effective, can spare patients from long and costly inpatient treatments.

Methods: Seventeen patients with cutaneous leishmaniasis were treated with cryosurgery using liquid nitrogen as the cryogen. Two cycles of 10-30 s freezing time were used and repeated at 3-week intervals.

Results: All patients responded well to therapy with excellent cosmetic results and no relapse in any case. Side-effects were rare.

Conclusions: Cutaneous leishmaniasis can be successfully treated with a simple protocol of cryosurgery with minor side-effects.

Citing Articles

Cutaneous Cryosurgery in Dermatology: Evolving Principles and Clinical Applications for Benign, Premalignant, and Malignant Lesions.

Mokbel R, Kodresko A, Mokbel K, Ghazal H, Trembley J, Jouhara H In Vivo. 2025; 39(2):577-612.

PMID: 40010951 PMC: 11884497. DOI: 10.21873/invivo.13865.

Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps.

Pacheco-Fernandez T, Markle H, Verma C, Huston R, Gannavaram S, Nakhasi H Res Rep Trop Med. 2023; 14:61-85.

PMID: 37492219 PMC: 10364832. DOI: 10.2147/RRTM.S392606.

Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.

Madusanka R, Silva H, Karunaweera N Infect Dis Ther. 2022; 11(2):695-711.

PMID: 35192172 PMC: 8960542. DOI: 10.1007/s40121-022-00602-2.

An overview of the treatment of cutaneous leishmaniasis.

Garza-Tovar T, Sacriste-Hernandez M, Juarez-Duran E, Arenas R Fac Rev. 2021; 9:28.

PMID: 33659960 PMC: 7886081. DOI: 10.12703/r/9-28.

Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Sundar S, Agrawal N, Singh B Expert Opin Drug Metab Toxicol. 2019; 15(7):595-612.

PMID: 31174439 PMC: 6640127. DOI: 10.1080/17425255.2019.1629417.